CAR T-cell therapy is a novel approach to cancer adoptive immunotherapy. The ongoing regulatory reforms, such as the breakthrough therapy designation (BTD) and priority review pathway, have…
The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug…
Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and…
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin (Hb) in red blood cells that distorts them into a sickle shape. This sickling leads to…
Immune thrombocytopenic purpura (ITP) is an autoimmune disease resulting in a low platelet count. Treatment of ITP involves the use of immunomodulators and corticosteroids as well as multiple…
Clarivate Epidemiology’s coverage of monoclonal gammopathy of undetermined significance (MGUS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to various…
Multiple myeloma is a hematologic malignancy that arises from an overproduction of plasma cells in the bone marrow. In patients with active disease, immunomodulatory drugs (e.g., Revlimid, Pomalyst…
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients…
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting Drill down into physicians’ treatment sequences and understand whom to position…